Leqembi
NICE Doesn't Recommend Biogen, Eisai's Alzheimer's Drug in Draft Guidance Despite MHRA Nod
After considering the data on Leqembi, the agency found that the four-to-six month slowing of disease progression wasn't enough benefit to justify its costs.
In Brief This Week: Eisai, Biogen, Kyverna Therapeutics, BMS
News items for the week of Aug. 5, 2024.
The company drew on data from prior studies and simulations to show what happens when patients stop receiving the beta-amyloid-targeting drug.
At AAIC, researchers showed the potential of long-term treatments with Roche’s gantenerumab in patients likely to develop dominantly inherited Alzheimer's.
EMA's CHMP Recommends Against Approval for Eisai, Biogen's Alzheimer's Drug Leqembi in Europe
The committee said the drug's modest clinical benefit doesn't outweigh its significant safety risks, but Eisai will ask the CHMP to reexamine its opinion.
Feb 8, 2024